The VP-Corporate Controller of Conmed is Exercising Options

By Carrie Williams

On December 2 it was reported that the VP-Corporate Controller of Conmed (CNMDResearch Report), Terence Berge, exercised options to sell 13,400 CNMD shares at $41.93 a share, for a total transaction value of $1.38M.

In addition to Terence Berge, 7 other CNMD executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Conmed’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $238 million and quarterly net profit of $6.85 million. In comparison, last year the company earned revenue of $234 million and had a net profit of $6.97 million. The company has a one-year high of $115.47 and a one-year low of $37.66. CNMD’s market cap is $2.99 billion and the company has a P/E ratio of -3309.30.

The insider sentiment on Conmed has been negative according to 36 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Terence Berge’s trades have generated a 7.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.